2017 sales at Boehringer Ingelheim rise nearly 16%

Boehringer Ingelheim can look back on a very successful 2017 financial year. All businesses contributed to net sales growth. R&D expenditure exceeded three billion euros ($3.7 billion), around 2.7 billion euros of which was in the human pharmaceuticals area alone, the German family-owned pharma major announced today.

Last year, Boehringer Ingelheim generated net sales of nearly 18.1 billion euros, representing an increase of 15.7% in currency-adjusted terms (+13.9% in euro terms). Adjusted for all the one-off effects that have resulted from the business swap with Sanofi, the company recorded currency-adjusted net sales growth of 6.1% (+4.4% in euro terms). With operating income of around 3.5 billion euros, up 21%, the return on net sales came to 19.3%.

“Human pharmaceuticals have performed very encouragingly sales-wise, exceeding our expectations. With an increase of 6.9% after adjustment for currency effects, we generated more than 12.6 billion euros in net sales. As such, we grew faster than the market and this area accounted for 70% of our total net sales,” commented Hubertus von Baumback, chairman on the board of managing directors.